Search Result

Results for "

actin depolymerization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Arp2/3 Complex (1) Antibiotic (1) Autophagy (1) Drug Metabolite (4) Endogenous Metabolite (4) Fluorescent Dye (1) Isotope-Labeled Compounds (2) nAChR (4) Reference Standards (1) ROCK (1) YAP (1) β-catenin (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (4) Infection (1) Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Arp2/3 Complex

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6682

Cytochalasin D 65+ Cited Publications Zygosporin A; NSC 209835	Arp2/3 Complex Antibiotic YAP	Infection Cancer
Cytochalasin D (Zygosporin A) is a potent **actin polymerization** inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap .

HY-N6772

Cytochalasin E	Autophagy	Cancer
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation .

HY-W002112

(±)-Nornicotine Nornicotine	Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W002112S

(±)-Nornicotine-d4	nAChR Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-N7550

Latrunculin M	Fluorescent Dye	Others
Latrunculin M is a highly selective actin-macrolide conjugate that can be isolated from marine products. Latrunculin M can be converted from Latrunculin B, which can effectively induce actin depolymerization and is a good probe for detecting the actin skeleton.

HY-151189

ROCK-IN-4	ROCK	Others
ROCK-IN-4 is a potent ROCK inhibitor maintaining NO releasing ability. ROCK-IN-4 reversibly depolymerizes F-actin, and suppresses mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be used for glaucoma or ocular hypertension research .

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W002112S1

(±)-Nornicotine-d7	Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6682

Cytochalasin D 65+ Cited Publications Zygosporin A; NSC 209835	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Arp2/3 Complex Antibiotic YAP
Cytochalasin D (Zygosporin A) is a potent **actin polymerization** inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap .

HY-N6772

Cytochalasin E	Alkaloids Structural Classification Microorganisms Pyrrole Alkaloids Classification of Application Fields Source classification Disease Research Fields Cancer	Autophagy
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation .

HY-W002112

(±)-Nornicotine Nornicotine	Structural Classification Alkaloids Pyrrole Alkaloids Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-N7550

Latrunculin M	Structural Classification Natural Products Marine natural products Source classification Sponge	Fluorescent Dye
Latrunculin M is a highly selective actin-macrolide conjugate that can be isolated from marine products. Latrunculin M can be converted from Latrunculin B, which can effectively induce actin depolymerization and is a good probe for detecting the actin skeleton.

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

Cat. No.	Product Name	Chemical Structure

HY-W002112S

(±)-Nornicotine-d4
(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

(±)-Nornicotine-d4

(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W002112S1

(±)-Nornicotine-d7
(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces *F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

(±)-Nornicotine-d7

(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks